

神経芽腫委員会

(主) Iehara T, Yoneda A, Kikuta A, Muraji T, Tokiwa K, Takahashi H, Teramukai S, Takimoto T, Yagyu S, Hosoi H, Tajiri T, JNBSG. A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol. *BMC Pediatr.* 20:212. 2020. PMID:32398048

腎腫瘍委員会

(主) 大植 孝治, 越永 従道, 野崎 美和子, 桑島 成子, 田中 祐吉, 大喜多 肇, 瀧本 哲也, 福本 弘二. JCCG 腎腫瘍委員会報告 両側 Wilms 腫瘍臨床研究 RTBL14 の結果 希少疾患に対する臨床試験施行上の問題点. *日本小児血液・がん学会雑誌.* 57:318. 2020.

肝腫瘍委員会

Fujiyoshi S, Honda S, Minato M, Ara M, Suzuki H, Hiyama E, Taketomi A. Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma. *Hepatol Res.* 50:598. 2020. PMID:31894653

Haeberle B, Rangaswami A, Krailo M, Czauderna P, Hiyama E, Maibach R, Lopez-Terrada D, Aronson DC, Alaggio R, Ansari M, Malogolowkin MH, Perilongo G, O'Neill AF, Trobaugh-Lotrario AD, Watanabe K, Schmid I, von Schweinitz D, Ranganathan S, Yoshimura K, Hishiki T, Tanaka Y, Piao J, Feng Y, Rinaldi E, Saraceno D, Derosa M, Meyers RL. The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. *Pediatr Blood Cancer.* 67:e28350. 2020. PMID:32383794

(主) Hiyama E, Hishiki T, Watanabe K, Ida K, Ueda Y, Kurihara S, Yano M, Hoshino K, Yokoi A, Takama Y, Nogami Y, Taguchi T, Mori M, Kihira K, Miyazaki O, Fuji H, Honda S, Iehara T, Kazama T, Fujimura J, Tanaka Y, Inoue T, Tajiri T, Kondo S, Oue T, Yoshimura K. Outcome and Late Complications of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. *J Clin Oncol.* 38:2488. 2020. PMID:32421442

檜山 英三、兒島 正人、栗原 將、佐伯 勇. 国際共同臨床試験. 小児外科. 52:710. 2020.

Honda S, Chatterjee A, Leichter AL, Miyagi H, Minato M, Fujiyoshi S, Ara M, Kitagawa N, Tanaka M, Tanaka Y, Shinkai M, Hatanaka KC, Taketomi A, Eccles MR. A MicroRNA Cluster in the DLK1-DIO3 Imprinted Region on Chromosome 14q32.2 Is Dysregulated in Metastatic Hepatoblastomas. *Front Oncol.* 10:513601. 2020. PMID:33282720

ユーイング委員会

(主) Chin M, Yokoyama R, Sumi M, Okita H, Kawai A, Hosono A, Koga Y, Sano H, Watanabe H, Ozaki T, Mugishima H, Japan Ewing Sarcoma Study Group (JESS). Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04. *Pediatr Blood Cancer.* 67:e28194. 2020. PMID:32077253

Umeda K, Miyamura T, Yamada K, Sano H, Hosono A, Sumi M, Okita H, Kamio T, Maeda N, Fujisaki H, Jyoko R, Watanabe A, Hosoya Y, Hasegawa D, Takenaka S, Nakagawa S, Chin M, Ozaki T, Japan Ewing Sarcoma Study Group. Prognostic and therapeutic factors influencing the clinical outcome of metastatic Ewing sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. *Pediatr Blood Cancer.* 68:e28844. 2020. PMID:33340261

リンパ腫委員会

Kada A, Fukano R, Mori T, Kamei M, Tanaka F, Ueyama J, Sekimizu M, Osumi T, Mori T, Koga Y, Ohki K, Fujita N, Mitsui T, Saito AM, Hashimoto H, Kobayashi R. A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. *Acta Med Okayama.* 74:89. 2020. PMID:32099255

AML 委員会

Hara Y, Shiba N, Yamato G, Ohki K, Tabuchi K, Sotomatsu M, Tomizawa D, Kinoshita A, Arakawa H, Saito AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki T, Hayashi Y. Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. *Br J Haematol.* 188:528. 2020. PMID:31612466

Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K, Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing. *Genes Chromosomes Cancer*. 59:160. 2020. PMID:31606922

Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, Ogoh H, Matsuo H, Adachi S, Taga T, Tomizawa D, Osato M, Soga T, Morishita K, Moritake H. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase. *Haematologica*. 105:2118. 2020. PMID:31649131

Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. *Blood Adv*. 4:4623. 2020. PMID:32991719

(主) Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). *Pediatr Blood Cancer*. 67:e28692. 2020. PMID:32886449

再発 ALL 委員会

(主) Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, Saito AM, Manabe A, Horibe K, Toyoda H. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group. *Int J Hematol*. 112:720. 2020. PMID:32761462

HLH/LCH 委員会

塩田曜子. 組織球系腫瘍の診断と治療. *日本臨牀*. 78:708. 2020

Hayase T, Saito S, Shioda Y, Imamura T, Watanabe K, Ohki K, Yoshioka T, Oh Y, Kawahara Y, Niiijima H, Imashuku S, Morimoto A. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell

histiocytosis in Japan. Int J Hematol. 112:560. 2020. PMID:32654047

森本哲. ランゲルハンス細胞組織球症 ～その細胞起源と細胞活性化機構. 炎症と免疫. 28:106. 2020.

ALL 委員会

Sakaguchi K, Imamura T, Ishimaru S, Imai C, Shimonodan H, Fujita N, Okada K, Taketani T, Kanai R, Tauchi H, Kato M, Kojima Y, Watanabe A, Deguchi T, Hashii Y, Kiyokawa N, Taki T, Saito AM, Horibe K, Manabe A, Sato A, Koh K. Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemia with chromosome 8q24/MYC rearrangement in Japan. Pediatr Blood Cancer. 67:e28341. 2020. PMID:32323914

(主) Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki T, Deguchi T, Hori T, Sanada M, Ohmori S, Haba M, Iguchi A, Arakawa Y, Koga Y, Manabe A, Horibe K, Ishii E, Koh K. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 136:1813. 2020. PMID:32845001

長期フォローアップ委員会

(主) Sato I, Sato I, Soejima T, Ishida Y, Maeda M, Koh K, Kamibeppu K. Simple change in logistic procedure improves response rate to QOL assessment: a report from the Japan Children's Cancer Group. J Patient Rep Outcomes. 4:48. 2020. PMID:32556617

(主) Nakajima S, Nakajima S, Sato I, Soejima T, Koh K, Kato M, Okamoto Y, Imamura T, Maeda M, Ishida Y, Manabe A, Kamibeppu K. Comparison of child and family reports of health-related quality of life in pediatric acute lymphoblastic leukemia patients after induction therapy. BMC Pediatr. 20:390. 2020. PMID:32814552

支持療法委員会

森 尚子, 加藤陽子, 新小田雄一, 大曾根眞也, 嘉数真理子, 佐野弘純, 篠田邦大, 矢野道広, 石田裕二, 斎藤雄弥, 澤田明久, 豊田秀実, 足立壯一, 福島啓太郎. 小児がん治療施設から見た緩和ケアの課題—JPLSG 施設調査より 第1報—. 日本小児血液・がん学会雑誌. 57:33. 2020.

加藤陽子, 森 尚子, 新小田雄一, 大曾根眞也, 嘉数真理子, 佐野弘純, 篠田邦大, 矢野道広, 石田裕二,

齋藤雄弥, 澤田明久, 豊田秀実, 足立壯一, 福島啓太郎. 小児がん患者に対する疼痛管理の現状と課題—JPLSG 施設調査より 第2報—. 日本小児血液・がん学会雑誌. 57:178. 2020.

遺伝性腫瘍委員会

中野嘉子. DICER1 症候群と遺伝性腫瘍. 遺伝性腫瘍, 20:124, 2020